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Histoplasma capsulatum is the most prevalent cause of fungal respiratory disease. The disease extent and outcomes are the result
of the complex interaction between the pathogen and a host’s immune system. The focus of our paper consists in presenting the
current knowledge regarding the multiple facets of the dynamic host-pathogen relationship in the context of the virulence arsenal
displayed by the fungus and the innate and adaptive immune responses of the host.
1.Introduction
Histoplasmosis was ﬁrst described in 1906 by Darling among
the workers of the Panama Canal [1], and it is currently
the most common cause of fungal respiratory disease with
almost 500,000 individuals acquiring the fungus each year
[2]. The etiologic agent responsible for histoplasmosis is
Histoplasma capsulatum, a thermally dimorphic fungus with
worldwide distribution. The fungus is primarily found in
soil, where it exists in a mycelia form. In the United States,
highly endemic areas include regions along the Mississippi
and Ohio River valleys, where seroprevalence studies have
shown that up to 80% of individuals are skin test positive
for histoplasmin [3].
The entry portal of H. capsulatum is through inhalation
of aerosolized of 2–4μm diameter microconidia [4]. Mor-
phogenesis is initiated after infection with the conidia devel-
oping into a 2–4μm oval yeast form. The fungus is rapidly
ingested by macrophages and neutrophils, but manages to
avoid intracellular destruction. Intracellular yeast can be
transported diﬀusely via the lymphatics and into the blood-
stream. Nevertheless, initial infection is typically contained
byinnateandadaptivehostresponses.Inimmunocompetent
individuals, the pulmonary disease is usually subclinical to
limited, typically with ﬂu-like symptoms, including fever,
cough, headaches, and myalgias. However, lethal disease can
occur in otherwise healthy individuals who acquire a large
inoculum infection. Additionally, severe primary infection is
more common and reactivation of latent infection occurs in
immunocompromised persons, particularly in HIV-infected
population and transplant recipients. Disseminated disease
occurs in a small fraction of infected individuals, but this
form of histoplasmosis continues to carry a high fatality rate
even in patients receiving appropriate medical treatment [5].
More recently, treatments with inhibitors of tumor necrosis
factor-α have been shown to place patients at high risk for
developing histoplasmosis [6].
2.H. capsulatum Virulence Factors
The characterized virulence determinants of H. capsulatum
are mainly surface expressed molecules that mediate the
interaction between the fungus and the host’s immune
cells allowing the pathogen to evade destruction by innate
immune response and facilitate the replication of the yeast in
its new environment.
Heat shock protein 60 (HSP60), which has important
roles in chaperoning intracellular proteins and supervising
adequate protein folding, has also recently been described
as an essential surface molecule, mediating the recognition
and phagocytosis of the yeast by macrophages [7]. It acts as
a ligand for CD11/CD18 macrophage receptor and, despite
low number of antigenic sites, the coupling with the CR32 International Journal of Microbiology
receptor is followed by rapid ingestion of the yeast. The
interaction between Histoplasma and macrophage through
HSP60 binding to CR3 results only in a mild host immune
reaction, as it does not lead to a signiﬁcant activation of
phagocytes in the absence of other costimulatory signals
[8]. This process allows the microorganism to survive and
replicate inside the host cells [9, 10].
Heat shock protein 82 (HSP82) is another important
molecule in normal development of H. capsulatum that also
participates in the response to cellular stresses; it binds to
a variety of cellular proteins, keeping them inactive until
they have reached their proper intracellular location or have
received the proper activation signal [11]. The role of HSP82
is further complicated by the thermal dimorphism displayed
by Histoplasma, since changes in temperature represent both
a stress inducer and a signal for yeast phase transformation.
Recently, Edwards et al. demonstrated that a reduction in
HSP82 decreases Histoplasma virulence in macrophages and
severelyimpairsthefungus’abilitytoinfectlungsinamurine
infection model [12]. This suggests that a low basal level
of HSP82 expression is suﬃcient only to preserve cellular
functions at mammalian body temperature, but not to
withstand other stresses encountered during infection. The
temperature values during febrile episodes in the host, for
example, represent one stress that requires HSP82 function,
and defective mutant strains show a decreased ability to
recover from transient in vitro incubation at 40◦C. However,
even at 37◦C these defective mutants showed decreased viru-
lence within macrophages, despite having identical growth
in culture at similar temperature; this implies that HSP82
extends its role to enduring additional, nonthermal stresses
during host infection. One example is the ability to survive
oxidative stress, as shown by peroxide challenge studies [12].
YPS3 is a yeast phase-speciﬁc gene encountered in a
subset of H. capsulatum strains. The encoded protein is
found both as a fungal cell wall constituent and as a secreted
molecule [13]. The exact function of this gene remains to
be determined, but its importance in virulence is a certainty,
since YPS3 mutants are attenuated in vivo [14].
The production of cell wall melanin is associated with
virulence for diverse fungi; H. capsulatum conidia and yeast
produce melanin or melanin-like pigments in vitro and
yeast cells are melanized during mammalian infections [15].
The melanization process decreases the susceptibility of the
fungus to amphotericin B and caspofungin and melanin can
abrogate the potency of certain host defense mechanisms,
such as free radicals and microbicidal peptides [16, 17].
Calcium-binding protein (CBP) represents another im-
portant factor in Histoplasma pathogenicity. CBP is secreted
by the fungal cells during the yeast-phase of intracellular
growth within the macrophage [18], and its importance
for the virulence of the fungus was demonstrated both
in vitro and in vivo. For example, CBP1 gene deletion
yeast cells were rapidly cleared from the lungs of infected
mice. Additionally, H. capsulatum growth is inhibited in
limiting calcium conditions [19]. One of the hypotheses
is that calcium acquisition represents an important factor
for intracellular survival of the microorganism; another
hypothesis targets the modulating eﬀect of CBP in binding
calcium to facilitate optimal phagolysosomal conditions for
yeast growth.
Many H. capsulatum strains express α-(1,3)-glucan on
their yeast cell surface. This polysaccharide forms a layer
that conceals cell surface β glucans, which have antigenic
properties, eluding the identiﬁcation by the host phagocytic
cells. The β glucan found in the cell wall of Histoplasma
and other fungi is recognized by the Dectin-1 receptor
on macrophages resulting in the triggered formation of
reactive oxygen species and secretion of proinﬂammatory
cytokines [20]. Conﬁrmatory evidence for the role of the
α-glucan was obtained using Ags-1-deﬁcient Histoplasma
mutant strains, where yeasts lacking the cell wall α-(1,3)-
glucan were attenuated for virulence [21].
Histone 2B (H2B) has also been found to play a role
in pathogenesis [22]. Histones are mainly intracellular com-
ponents, but a study investigating passive immunity through
administration of monoclonal antibodies from mice im-
munized with Histoplasma revealed antibody recognition of
H2Bpresentonthecellwall.Themeansbywhichhistorically
intracellular-based molecules, as HSP60 or H2B, reach the
yeast cell wall where they can interact with host cells was
unclear until recently when macromolecular transport to the
extracellular space was demonstrated to occur via vesicular
secretion and active vesicular transport [23, 24].
Hydroxamate siderophores production by Histoplasma is
another newly characterized virulence factor. Strains defec-
tive for the gene coding for siderophore production display
impaired intracellular growth in both human and murine
macrophages, which can be reversed by either exogenous
iron addition or restoration of SID1 expression [25, 26].
3. Host Defense Mechanisms
After being exposed to Histoplasma, the host relies on both
innate and adaptive immune response mechanisms to neu-
tralize the pathogen and withstand infection. Macrophages
and dendritic cells have major roles in the activation of
cellular pathways, and the numerous cytokines, especially
IFN-γ and TNF-α, signiﬁcantly impact host responses.
Macrophages have a central role in the interaction
between the fungus and the host, although their contri-
bution has a dual nature. They represent the ﬁrst line of
defense during infection with H. capsulatum, as they rapidly
phagocytose the inhaled conidia and transforming yeast
cells, and the infected macrophage subsequently activate
eﬀector T cells and enhance the release of Th1-associated
proinﬂammatory cytokines (IL-12, IFN-γ,a n dT N F - α)[ 27,
28]. Deprivation of zinc and iron is amongst the means
used by macrophages to neutralize the intruding pathogen
[29], along with production of superoxide, nitric oxide, and
lysosomal hydrolysis. However, the fungus displays various
mechanisms to elude destruction after phagocytosis. For
example, H. capsulatum yeast cells are able to regulate the
pH of the phagolysosomes at a neutral pH (approximately
pH 6.5), where lysosomal hydrolases have decreased activity.
Hence, the H. capsulatum yeast cells manage to survive and
even replicate inside macrophages [30].International Journal of Microbiology 3
Dendriticcellsarealsoanimportanteﬀectoroftheinnate
immunity. They are able to phagocytose and degrade the
fungal cells with higher eﬃcacy than macrophages, which
might be due to recognition of the pathogen via a diﬀerent
type of receptor (ﬁbronectin receptor on dendritic cells
versus CD18 on macrophages) [31]. Dendritic cells also are
extremely eﬃcient at processing and presenting antigens to
speciﬁc CD8 T cells, either following ingestion of the yeast,
or through “cross presentation” of fungal antigens engulfed
from infected apoptotic macrophages [32]. In a recent study,
the addition of antigen-presenting dendritic cells was found
to suppress excessive production of IL-4 by CD4 T cells in
lungs of CCR2-deﬁcient mice infected with H. capsulatum,
demonstrating the importance of these cells in the regulation
of immune responses [33].
Cellular immunity is crucial in the host defense against
intracellular pathogens; therefore, T cells, as the central
eﬀectors of the cellular immunity, have a substantial role
in neutralizing H. capsulatum yeast cells. Mice depleted of
both CD4 and CD8 T cells have accelerated time to death
after challenge with H. capsulatum yeast cells, especially
in a primary histoplasmosis model, which underlines the
importance of the interaction between the two cell subsets
in withstanding Histoplasma infection by eliciting a Th1
response [34]. CD4 cell depletion is associated with survival
during primary infection, as a result of impaired IFN-
γ production. The elimination of CD8 T cells results
in decreased clearance of yeast cells in primary but not
secondaryinfection.Oneparticularsubpopulation ofTcells,
Vβ4+ Tcells,ispreferentiallyexpendedduringinfectionwith
H. capsulatum, and elimination of these cells from mice
impairs their ability to resolve infection [35]. Th17 T cells
and their interaction with regulatory T cells have recently
been linked via the chemoattractant mediator CCR5 to the
host’s ability to eﬀectively combat H. capsulatum infection;
increases in Th17 cytokines and reductions in the number
of regulatory T cells were associated with accelerated fungal
clearance in CCR5-deﬁcient animals [36].
Although cytokine responses are complex in histoplas-
mosisandalteroverthecourseofdisease,themaincytokines
involved in Histoplasma clearance from the host are IL-
12, IFN-γ,a n dT N F - α [34]. IL-12 through its ability to
regulate IFN-γ production is critical in inducing a protective
immune response in primary infection with the pathogen.
IFN-γ is pivotal for the host’s innate resistance to systemic
infectionwithH.capsulatum.Survivalofmiceissigniﬁcantly
reduced in IFN-γ- d e ﬁ c i e n tm i c ea sw e l la si nw i l d - t y p em i c e
treated with neutralizing antibody to IFN-γ [37]. Patients
with impaired IFN-γ signaling due to genetic defects are at
increased risk for severe disease forms and administration
of the cytokine can be therapeutic. For example, a report
of recurrent disseminated H. capsulatum osteomyelitis in a
patient with genetic IFN-γ receptor 1 deﬁciency describes
progressive clearing of all bone lesions and normalization
of inﬂammatory markers following subcutaneous therapy
with IFN-γ [38]. Although IFN-γ is critical in primary
infection, survival in secondary infection can be achieved in
the absence of IFN-γ, as immunization of IFN-γ-deﬁcient
mice with an initial sublethal inoculum can prolong the
survival of these mice when subsequently challenged with
a high concentration of H. capsulatum yeast cells [39]. The
major mechanism by which these mice were able to control
secondary infection was through increased production of
TNF-α.
TNF-α is a key modulator of disease in both primary
and secondary histoplasmosis, though diﬀerent protective
mechanisms are involved in these conditions [34, 40]. In
primary infection, decreased survival of TNF-α-deﬁcient
mice has been attributed to an impaired ability to generate
reactive nitrogen intermediates in the alveolar macrophages,
although inducible nitric oxide synthase expression in lung
tissueispreserved.Duringsecondaryinfection,theincreased
mortality is largely due to a biased host reaction to a
Th2-type response that is associated with elevated levels
of both IL-4 and IL-10. These ﬁndings parallel the clinical
data that clearly demonstrates that therapy with TNF-α
inhibitors poses a signiﬁcant increased risk for reactivation
of latent histoplasmosis with a greater likelihood of severe,
disseminated disease [8].
H u m o r a li m m u n er e s p o n s e sg e n e r a l l yh a v eal i m i t e d
role in the clearance of intracellular pathogens; however,
the protective role of antibodies against surface molecules
of H. capsulatum has been described. Administration of
monoclonal antibodies to Histoplasma H2B reduces fungal
burden, decreases pulmonary inﬂammation, and prolongs
survival in murine infection models [22]. The protective
response was associated with increased levels of IL-4, IL-6,
and IFN-γ. Similarly, antibodies to H. capsulatum HSP60
prolong the survival of the lethally infected animals [41, 42].
4. Discussion
Histoplasmosis is the most common endemic dimorphic
fungal pathogen of man. The continuously expanding pop-
ulation of immunocompromised patients, secondary to the
ongoing HIV epidemic, the increasing use of immuno-
suppressant therapies and rising number of transplant re-
cipients, represents a high risk cohort for histoplasmosis.
The mortality rate associated with invasive histoplasmosis is
still unacceptably high, despite the use of broad spectrum
antifungal agents, which emphasizes the need for developing
novel therapies and eﬀective preventive strategies.
As outlined in this paper, targeting virulence determi-
nants of H. capsulatum and attempts to modify the capacity
of the host to respond to the fungal invader are actively
being pursued by researchers. Recent studies investigating
the capacity of H. capsulatum to release a large number
of proteins and other immunologically active compounds
[23, 24, 43, 44] demonstrate the breadth of the fungus’
ability to modify host responses. The high frequency of
disease in the endemic areas and the increasing prevalence
of the disseminated disease forms justify the development
of adequate immunization strategies. Most recently, data
has shown that vaccine-induced fungus-speciﬁc Th17 cells
can confer protection against pulmonary histoplasmosis
by recruiting and activating neutrophils and macrophages
to the alveolar space [45]. Harnessing the host’s existing4 International Journal of Microbiology
armamentarium or supplementing the host’s capacity, such
as with the administration of cytokines or antibody to H.
capsulatum, will be rich areas of study for the future.
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